Drug
Rezafungin clinical trials
- studies test it
- 10
- open now
- 1
- in phase 3
- 3
- first study started
- 2015
Keep track of what changes. Save the Rezafungin studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Development codes
Studies by the year they started
10 studies that test it; most in 2015 (2)
| Year | Studies |
|---|---|
| 2015 | 2 |
| 2016 | 2 |
| 2018 | 1 |
| 2019 | 1 |
| 2020 | 1 |
| 2024 | 1 |
| 2025 | 1 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 4
- Phase 2
- 2
- Phase 3
- 3
- Phase 4
- 1
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 6 · Other 4
Cidara Therapeutics Inc. (5) · Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal (1) · Mundipharma Research Limited (1) · Fernanda P Silveira, MD, MS (1) · National Institute of Allergy and Infectious Diseases (NIAID) (1) · Hartford Hospital (1)
Studies
Open first, then newest update. How each study uses Rezafungin is read from its arms, and is right about nine times in ten.
Testing it · 10
- Rezafungin Prophylaxis in Liver TransplantEnrolling by invitationPhase 3Fernanda P Silveira, MD, MSNCT06774144Written as Rezafungin
- Pharmacokinetic Study of Rezafungin in Patients With Suspected Intra-Abdominal CandidiasisActive, not recruitingPhase 4Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y CajalNCT06985758Written as Rezafungin 400mg followed by weekly doses of intravenous Rezafungin 200mg
- Study of Rezafungin Compared to Standard Antimicrobial Regimen for Prevention of Invasive Fungal Diseases in Adults Undergoing Allogeneic Blood and Marrow TransplantationCompletedPhase 3Mundipharma Research LimitedNCT04368559Written as Rezafungin for Injection
- Rezafungin Pharmacokinetics in Patients on ECMOWithdrawnPhase 1Hartford HospitalNCT06329518Written as Rezafungin
- A Single Ascending Dose Study of CD101 IV in Healthy SubjectsCompletedPhase 1Cidara Therapeutics Inc.NCT02516904Written as CD101 IV
- Study of Rezafungin Compared to Caspofungin in Subjects With Candidemia and/or Invasive CandidiasisCompletedPhase 3Cidara Therapeutics Inc.NCT03667690Written as Rezafungin for Injection
- Safety and Pharmacokinetics of RezafunginTerminatedPhase 1National Institute of Allergy and Infectious Diseases (NIAID)NCT04117607Written as Rezafungin
- CD101 Compared to Caspofungin Followed by Oral Step Down in Subjects With Candidemia and/or Invasive Candidiasis-Bridging ExtensionCompletedPhase 2Cidara Therapeutics Inc.NCT02734862Written as CD101
- RADIANT: CD101 vs Standard of Care in Subjects With Acute Vaginal Yeast InfectionsCompletedPhase 2Cidara Therapeutics Inc.NCT02733432Written as CD101 Vaginal Gel (3%)
- An Ascending Multiple Dose Study of CD101 IV in Healthy SubjectsCompletedPhase 1Cidara Therapeutics Inc.NCT02551549Written as CD101 IV
Codes
What other systems call Rezafungin · ClinicalTrials.gg INT001033
- MeSH (NLM) C000629634RezafunginConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) G013B5478JREZAFUNGINConfirmed FDA, NLM
- NCI Thesaurus C152205RezafunginOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000629634 | Rezafungin | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | G013B5478J | REZAFUNGIN | Confirmed FDA, NLM |
| NCI Thesaurus | C152205 | Rezafungin | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.